Attached files
| file | filename |
|---|---|
| EX-31.2 - EX-31.2 - iTeos Therapeutics, Inc. | itos-ex312_7.htm |
| EX-31.1 - EX-31.1 - iTeos Therapeutics, Inc. | itos-ex311_6.htm |
| 10-Q - 10-Q - iTeos Therapeutics, Inc. | itos-10q_20200630.htm |
Exhibit 32.1
CERTIFICATION PURSUANT TO
18 U.S.C. SECTION 1350,
AS ADOPTED PURSUANT TO
SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002
Pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, Michel Detheux, the Chief Executive Officer, and Matthew Gall, the Chief Financial Officer, of iTeos Therapeutics, Inc. (the “Company”), hereby certify, that, to their knowledge:
|
|
(1) |
the Quarterly Report on Form 10-Q for the period ended June 30, 2020 (the “Report”) of the Company fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and |
|
|
(2) |
the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company. |
|
Date: September 1, 2020 |
By: |
/s/ Michel Detheux |
|
|
|
Michel Detheux |
|
|
|
President, Chief Executive Officer and Director |
|
|
|
(Principal Executive Officer) |
|
|
|
|
|
|
|
|
|
Date: September 1, 2020 |
By: |
/s/ Mathew Gall |
|
|
|
Matthew Gall |
|
|
|
Chief Financial Officer |
|
|
|
(Principal Financial Officer and |
|
|
|
Principal Accounting Officer) |